TAK-020
TAK-020 is a covalent Btk inhibitor, which becomes the clinical candidate.
Product Specifications
CAS Number
[1627603-21-7]
UNSPSC
12352005
Target
Btk
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/tak-020.html
Purity
99.93
Solubility
DMSO : 20.83 mg/mL (ultrasonic; warming; heat to 80°C)
Smiles
O=C1NNC(C2=CC3=C(C(O[C@@H]4CN(C(C=C)=O)CC4)=N2)C=CC=C3)=N1
Molecular Formula
C18H17N5O3
Molecular Weight
351.36
References & Citations
[1]Sabat M, et al. Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S) -5- (1- ((1-Acryloylpyrrolidin-3-yl) oxy) isoquinolin-3-yl) -2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design. J Med Chem. 2021 Sep 9;64 (17) :12893-12902.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6264976-01 0.1 mL
MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass
Ask
View Details 
MBS6264976-02 5x 0.1 mL
MUC1 (Mucin-1, MUC-1, Breast Carcinoma-associated Antigen DF3, Cancer Antigen 15-3, CA 15-3, Carcinoma-associated Mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive Urinary Mucin, PUM, Polymorphic Epithelial Mucin, PEM, Tumor-ass
Ask
View Details